Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Indivior ( (GB:INDV) ) has provided an announcement.
Indivior PLC has announced changes to its Board of Directors, following discussions with Oaktree Capital Management. The company appointed Robert Schriesheim and Joe Ciaffoni as independent non-executive directors, aligning its board practices with US standards. These changes are part of a broader strategy to enhance operations and create long-term value for shareholders. This restructuring comes amid efforts to address short-term business challenges, including streamlining actions across various departments and executing a share repurchase program. Indivior’s collaboration with Oaktree reflects a commitment to improving its operational execution and shareholder value.
More about Indivior
Indivior is a global pharmaceutical company based in Richmond, VA, focusing on developing medicines to treat substance use disorders, overdose, and serious mental illnesses. The company’s vision is to ensure global access to evidence-based treatment for substance use disorders, and it offers a range of products available in over 30 countries.
YTD Price Performance: -23.38%
Average Trading Volume: 498,374
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.16B
For detailed information about INDV stock, go to TipRanks’ Stock Analysis page.
